Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways

Ira J. Goldberg,1,* Robert H. Eckel,† and Nada A. Abumrad§

Division of Preventive Medicine and Nutrition,* Department of Medicine, Columbia University, New York, NY; Division of Endocrinology, Diabetes, and Metabolism,† University of Colorado at Denver, Aurora, CO; Department of Medicine,§ Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO

Abstract Cells obtain FAs either from LPL-catalyzed hydrolysis of lipoprotein triglyceride or from unesterified FFA associated with albumin. LPL also influences uptake of esterified lipids such as cholesteryl and retinyl esters that are not hydrolyzed in the plasma. This process might not involve LPL enzymatic activity. LPL is regulated by feeding/fasting, insulin, and exercise. Although a number of molecules may affect cellular uptake of FFAs, the best characterized is CD36. Genetic deletion of this multiligand receptor reduces FFA uptake into skeletal muscle, heart, and adipose tissue, and impairs intestinal chylomicron production and clearance of lipoproteins from the blood. CD36 is regulated by some of the same factors that regulate LPL, including insulin, muscle contraction, and fasting, in part, via ubiquitination. LPL and CD36 actions in various tissues coordinate biodistribution of fat-derived calories.—Goldberg, I. J., R. H. Eckel, and N. A. Abumrad. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J. Lipid Res. 2009. 50: S86–S90.

LIPID UPTAKE VIA THE LIPOLYSIS PATHWAY

The importance of the lipolysis reaction in the catabolism of TG-rich lipoproteins was shown more than 50 years ago by the discovery that intravenous heparin injection leads to the release of LPL into the plasma and reduces postprandial lipemia. Subsequent studies established that LPL is robustly expressed in tissues like adipose and muscle that require large influxes of FAs for storage or energy and that LPL is the primary enzyme responsible for chylomicron- and VLDL-TG lipolysis. However, several questions on the role of this enzyme in fuel partitioning and tissue lipid uptake, its regulation, and its importance for vascular biology remained to be answered.

Genetic modulation of LPL protein and its sites of expression have partially elucidated how LPL affects physiology and has confirmed prior in vitro studies. Although humans with LPL deficiency develop severe hypertriglyceridemia and are at risk for pancreatitis, mice with spontaneous or genetic loss of LPL die within 24 h of birth. Prior to death, LPL-deficient mice develop hypoglycemia, a process that is partially abrogated by ketone body production via LPL expression in the liver (1). In contrast, tissuespecific overexpression of LPL in skeletal muscle and liver increased cellular stores of TG and probably other lipids and led to insulin resistance (2). Loss of LPL in adipose tissue and its overexpression in skeletal muscle reduced adipose development when these mice were crossed onto the obesity ob/ob background (3). However, in nonobese mice, adipose stores were normal. This suggests compensation by de novo TG synthesis or uptake of plasma lipids through other pathways (4). In pancreatic β cells, both overexpression and deletion of LPL impaired insulin secretion (5). Although tissue-specific effects of LPL are still being explored, the initial hypothesis of Greenwood (6) that LPL serves as a “gatekeeper” to direct calories to specific tissues is clearly correct.
LPL increases uptake of lipids other than TG (Fig. 1), e.g., selective uptake of cholesteryl esters by skeletal muscle is mediated by catalytically inactive LPL (7). LPL might act like a neutral lipid transfer protein, akin to cholesteryl ester transfer protein, or during remodeling of the lipoprotein particle, small lipid particles containing core and surface lipid and protein exclusive of apoB could be shed from the lipoproteins. These particles would be similar or perhaps identical to the lipid/apoprotein complexes that are known to transfer to HDL. LPL also augments LDL uptake either by approximation of LDL to the LDL receptor or by uptake along with recycling of proteoglycans on the cell surface. The recent development of a mouse with a defect of proteoglycan sulfation associated with increased postprandial lipemia (8) is consistent with this type of lipoprotein uptake process.

Using heart-specific LPL knockout mice, the role of LPL was studied in the setting of normal uptake of FFA. The presence of a marked increase in glucose uptake (9) and the development of heart dysfunction with aging and increased afterload (10) confirmed that FFAs cannot substitute for loss of LPL. As had been reported in vitro (11, 12), reduction in peroxisome proliferator-activated receptor (PPAR) downstream gene expression confirmed the hypothesis that LPL creates ligands for this transcription factor.

Metabolism of fat-soluble vitamins is also affected by LPL actions. Overexpression of LPL in skeletal muscle increased α-tocopherol (13). Dietary retinyl ester is a marker for chylomicron metabolism. Tissue vitamin A circulates in chylomicrons and in association with circulating retinol binding protein. Retinol binding protein knockout mice are visually impaired at birth, a defect that improves as the mice age (14). This is likely due to tissue acquisition of dietary retinyl ester, a process that correlates with LPL expression (15).

Arterial expression of LPL is a marker of atherosclerosis. Zilversmit postulated that LPL converts chylomicrons into atherogenic remnant lipoproteins (16). Lack of LPL in macrophages leads to less atherosclerosis (17). However, mechanisms other than those originally postulated might be operative. LPL increases the association of LDL with matrix; FFAs and lipolysis alter endothelial cell barrier function and cause vascular inflammation (18).

**NUTRITIONAL AND HORMONAL REGULATION OF LPL**

LPL actions within tissues are modulated at both the transcriptional and posttranscriptional levels. The latter might involve actions of the glycosylphosphatidylinositol HDL binding protein (GPIHBP) protein (19), angiopoietin-like proteins, which reduce LPL dimer formation (20), and the recently described lipase maturation factor (21). LPL regulation is tissue specific. LPL is present in the liver during fetal and early postnatal life but is then suppressed by a putative transcriptional regulatory mechanism, perhaps involving a novel transcription factor, termed RF-1-LPL, which binds to an NF-1-like site in the region of the glucocorticoid response element. This extinction of the hepatic expression of LPL is also under the influence of thyroid hormone and glucocorticoids.

In the mammary gland, synthesis of LPL is induced during late pregnancy and lactation, perhaps via the effects of prolactin (22). Partially dedifferentiated and delipidated adipocytes, rather than epithelial cells, are the source of the lipase. In brown adipose tissue, LPL activity is increased during cold exposure by both a transcriptional and translational/posttranslational mechanism that involves β-adrenergic stimulation. Stress, both chronic and acute, decreases LPL activity in white adipose tissue but increases the LPL activity in cardiac and skeletal muscle and the adrenal glands. These changes may be mediated by catecholamines (23).

The LPL response to feeding and fasting is also tissue specific. In rodents and humans, this regulation in white adipose tissue and muscle exists mostly at the posttranslational level. Adipose tissue LPL activity is high after feeding and low during fasting, whereas in most studies, the opposite is true in the heart and skeletal muscle. Although in human subjects an insulin infusion had a divergent effect on LPL activity in adipose tissue (increased) and skeletal muscle

![Fig. 1](image-url)  
**Fig. 1.** LPL-mediated uptake of lipids. Left panel: LPL hydrolyzes lipoprotein TG releasing FFAs that are internalized by cells. Much of this uptake is via cell surface receptors such as CD36. Middle panel: LPL also creates remnant lipoproteins that interact with cell surface lipoprotein receptors. Right panel: Another option for uptake of core lipids is that lipolysis creates small particles that contain both surface and core lipid as well as apoproteins, exclusive of apoB. Inactive LPL (iLPL) on the cell surface might facilitate cellular internalization of these particles. Such a pathway might allow cholesteryl and retinyl ester uptake into “high lipolysis” organs such as the heart.
Regulation of FFA uptake via the FA translocase CD36

FFAs liberated from circulating lipoproteins and FFAs bound to albumin transfer into the cell via predominantly a saturable protein-facilitated process (27, 28). Several proteins have been implicated in facilitating FA uptake and more may still await identification, but the scavenger receptor CD36 has been the best characterized as a FA translocase. First identified on platelets as GPIV, an 88-kDa thrombospondin and collagen receptor, CD36 was linked to lipid metabolism in 1993 when it acquired two new functions as a macrophage receptor for oxidized LDL and as an adipocyte receptor/transporter for long-chain FAs. CD36 membrane topology is proposed to include two transmembrane domains with both N and C termini in the cytoplasm (29). The purified protein binds long- but not short-chain FAs in vitro and a putative FA binding site (residues 127 and 279) was postulated based on similarity of the predicted CD36 secondary sequence with that of human muscle FA binding protein (30).

CD36 deficiency in mice significantly impairs FA uptake by heart, skeletal muscle, and adipose tissue (31). Fasting plasma TG and FA levels are increased. The decrease in muscle FA utilization enhances insulin sensitivity of the tissue (32) and is protective against diet-induced obesity (33). Muscle-targeted CD36 overexpression reduces levels of plasma FAs and TG (34) and associates with hyperglycemia and hyperinsulinemia. In the spontaneously hypertensive rat, mutations in the CD36 gene were linked to the hyperlipidemia and insulin resistance observed in this model and the symptoms were improved by transgenic expression of wild-type CD36 (35).

CD36 is expressed throughout the digestive tract including on taste bud cells in the tongue (36), in the stomach, the small intestine, and the colon (37). In the small intestine, CD36 exhibits a proximal to distal decreasing expression gradient (38). It is now clear that the protein plays an important role in chylomicron production (39) in part by facilitating uptake of FA and cholesterol by proximal enterocytes (38) where chylomicron formation is most efficient. CD36 may also facilitate intracellular trafficking of FAs and cholesterol for packaging into lipoproteins, but this remains to be explored. Despite the proximal defects in lipid uptake and chylomicron formation, net intestinal lipid absorption is not altered except for very-long chain FAs (40). However, the slowed absorption is associated with a reduction in fat intake (41). Clearance of blood lipoproteins is also defective in CD36 null mice, which may reflect feedback inhibition of tissue LPL by FA (39, 42).

CD36 binding and uptake of FA at the level of taste bud cells may contribute to fat taste perception and to the regulation of fat preference (36, 41). FA interaction with the protein triggers a signaling cascade that results in neurotransmitter release and relay of signal to the central nervous system (43). In the small intestine, production of the satiety messenger oleoylthanolamide after fat ingestion is dependent on CD36-facilitated oleic acid uptake (44).

In muscle, CD36 levels are chronically upregulated by insulin and muscle contraction (45). CD36 is a gene target of the PPAR in a tissue-specific fashion. In muscle during fasting, activation of PPARα upregulates CD36 to increase FA utilization (46).

CD36 function is acutely regulated by changes in its subcellular distribution; the protein is present in intracellular vesicles (e.g., endosomes, endoplasmic reticulum, and lysosomes) and on mitochondria (47). The forkhead transcription factor FOXO1 (48) activated with low insulin states, AMP-activated protein kinase activation, and muscular contraction (45) recruits muscle CD36 from intracellular stores to the plasma membrane and enhance FA uptake. The signaling pathways involved in CD36 trafficking are largely unclear, but a role of the small GTPase Rab11a and its effector proteins has been suggested (45). CD36 trafficking may also be regulated by alteration of its ubiquitination, which modifies its protein interactions, subcellular distribution, and turnover (49). CD36 ubiquitination on lysines 469 and 472 in the C-terminal domain is inhibited by insulin and enhanced by FAs (50).

Common polymorphisms in the CD36 gene that significantly affect blood lipid levels and susceptibility to metabolic disease have been identified in humans (51). CD36 deficiency is relatively common (2–7%) in persons of Asian and African descent and is associated with many of the phenotypic alterations described in rodents, such as abnormal-
ities of blood lipids, delayed clearance of blood FAs and TG, and defective FA uptake by the myocardium (52).

CONCLUSIONS

There is a redundancy of the pathways that mediate uptake of FAs and also of fat-soluble vitamins. The uptake pathways involving LPL and CD36 appear to be modulated under the same physiologic and pathological conditions. How these pathways overlap and the molecular details of their regulation remains unclear but can now be studied in genetically modified animals.

REFERENCES

1. Merkel, M. P., H. Weinstock, T. Chajek-Shaul, H. Radner, B. Yin, J. L. Breslow, and I. J. Goldberg. 1998. Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia. J. Clin. Invest. 102: 893–901.

2. Kim, J. K., J. J. Fillmore, Y. Chen, C. Yu, I. K. Moore, M. Pypaert, E. P. Lutz, Y. Kako, W. Velez-Carrasco, I. J. Goldberg, et al. 2001. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA. 98: 7522–7527.

3. Weinstock, P. H., S. Levak-Frank, L. C. Hudgins, H. Radner, J. N. Friedman, R. Zechner, and J. L. Breslow. 1997. Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. Proc. Natl. Acad. Sci. USA. 94: 10261–10266.

4. Kratky, D., R. Zimmermann, E. M. Wagner, J. G. Strauss, W. Jin, G. M. Kostner, G. Haemmerle, D. J. Rader, and R. Zechner. 2005. Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue. J. Clin. Invest. 115: 161–167.

5. Pappan, K. L., Z. Pan, G. Kwon, C. A. Marshall, T. Coleman, I. J. Goldberg, M. L. McDaniel, and C. F. Senemakwich. 2005. Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion. J. Biol. Chem. 280: 9023–9029.

6. Greenwood, M. R. 1985. The relationship of enzyme activity to feeding behavior in rats: lipoprotein lipase as the metabolic gatekeeper. Int. J. Obs. 9 (Suppl. 1): 67–70.

7. Merkel, M., J. Heeren, W. Dudek, F. Rinninger, H. Radner, J. L. Breslow, I. J. Goldberg, R. Zechner, and H. Greten. 2002. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J. Biol. Chem. 277: 7405–7411.

8. MacArthur, J. M., J. R. Bishop, K. I. Stanford, L. Wang, A. Bensadoun, J. L. Witzum, and J. D. Esko. 2007. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 117: 153–164.

9. Augustus, A., H. Yagyu, G. Haemmerle, A. Bensadoun, R. K. Vikramadithyan, S. Y. Park, J. K. Kim, R. Zechner, and I. J. Goldberg. 2004. Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J. Biol. Chem. 279: 25050–25057.

10. Augustus, A. S., J. Buchanan, T. S. Park, K. Hirata, H. L. Noh, J. Sun, S. Homma, J. D’Armento, E. D. Abel, and I. J. Goldberg. 2006. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J. Biol. Chem. 281: 8716–8725.

11. Ziouzenkov, O., S. Perrey, L. Asatryan, J. Hwang, K. L. MacNault, D. E. Moller, D. J. Rader, A. Sevianian, R. Zechner, G. Hoeffler, et al. 2003. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc. Natl. Acad. Sci. USA. 100: 1268–1275.

12. Chawla, A., C. H. Lee, Y. Barak, W. He, J. Rosenfeld, D. Liao, J. Han, H. Kang, and R. M. Evans. 2003. PPARdelta is a very low-density lipoprotein receptor in macrophages. Proc. Natl. Acad. Sci. USA. 100: 1268–1275.
35. Pravenec, M., V. Landa, V. Zidek, A. Musilova, V. Kren, L. Kadaova, T. J. Aitman, A. M. Glazier, A. Ibrahimími, N. A. Abumrad, et al. 2001. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. *Nat. Genet.* **27**: 156–158.

36. Laugerette, F., P. Passilly-Degrace, B. Patris, I. Niot, M. Febbraio, J. P. Montmayeur, and P. Besnard. 2005. CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. *J. Clin. Invest.* **115**: 3177–3184.

37. Chen, M., Y. Yang, E. Braunstein, K. E. Georgeson, and C. M. Harmon. 2001. Gut expression and regulation of FAT/CD36: possible role in fatty acid transport in rat enterocytes. *Am. J. Physiol. Endocrino. Metab.* **281**: E916–E923.

38. Nassir, F., B. Wilson, X. Han, R. W. Gross, and N. A. Abumrad. 2007. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. *J. Biol. Chem.* **282**: 19493–19501.

39. Drover, V. A., M. Ajmal, F. Nassir, N. O. Davidson, A. M. Nauli, D. Sahoo, P. Tso, and N. A. Abumrad. 2005. CD36 deficiency impairs intestinal lipid secretion and clearance of chylomicrons from the blood. *J. Clin. Invest.* **115**: 1290–1297.

40. Drover, V. A., D. V. Nguyen, C. C. Bastie, Y. F. Darlington, N. A. Abumrad, J. E. Pessin, E. London, D. Sahoo, and M. C. Phillips. 2008. CD36 mediates both cellular uptake of very long chain fatty acids and their intestinal absorption in mice. *J. Biol. Chem.* **283**: 13108–13115.

41. Schafani, A., K. Ackroff, and N. A. Abumrad. 2007. CD36 gene deletion reduces fat preference and intake but not postoral fat conditioning in mice. *Am. J. Physiol. Regul. Integ. Corp. Physiol.* **293**: R1823–R1832.

42. Goudriaan, J. R., M. A. den Boer, P. C. Rensen, M. Febbraio, F. Knipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol. 2005. CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. *J. Lipid Res.* **46**: 2175–2181.

43. El-Yassimi, A., A. Hichami, P. Besnard, and N. A. Khan. 2008. Linoleic acid induces calcium signaling, Src kinase phosphorylation, and neurotransmitter release in mouse CD36-positive gustatory cells. *J. Biol. Chem.* **283**: 12949–12959.

44. Schwartz, G. J., J. J. Fu, G. Astarita, X. Li, S. Gaetani, P. Campolongo, V. Cuono, and D. Pionelli. 2008. The lipid messenger OEA links dietary fat intake to satiety. *Cell Metab.* **8**: 281–288.

45. Schwenk, R. W., J. J. Luiken, A. Bonen, and J. F. Glatz. 2008. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. *Cardiovasc. Res.* **79**: 249–258.

46. Nahle, Z., M. Hsieh, T. Pietka, C. T. Coburn, P. A. Grimaldi, M. Q. Zhang, D. Das, and N. A. Abumrad. 2008. CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-mediated adaptation to metabolic stress. *J. Biol. Chem.* **283**: 14317–14326.

47. Holloway, G. P., J. J. Luiken, J. F. Glatz, L. L. Spriet, and A. Bonen. 2008. Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. *Acta Physiol (Oxf).* **194**: 293–309.

48. Bastie, C. C., Z. Nahle, T. McLoughlin, K. Esser, W. Zhang, T. Unterman, and N. A. Abumrad. 2005. FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and -independent mechanisms. *J. Biol. Chem.* **280**: 14222–14229.

49. Miranda, M., and A. Sorkin. 2007. Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. *Mol. Interv.* **7**: 157–167.

50. Smith, J., X. Su, R. El-Maghrabi, P. D. Stahl, and N. A. Abumrad. 2008. Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. *J. Biol. Chem.* **283**: 13578–13585.

51. Love-Gregory, L., R. Sherva, L. Sun, J. Wasson, T. Schappe, A. Doria, D. C. Rao, S. C. Hunt, S. Klein, R. J. Neuman, et al. 2008. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. *Hum. Mol. Genet.* **17**: 1695–1704.

52. Yamashita, S., K. I. Hirano, T. Kuwasako, M. Janabi, Y. Toyama, M. Ishigami, and N. Sakai. 2007. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. *Mol. Cell. Biochem.* **299**: 19–22.